image
Healthcare - Biotechnology - NASDAQ - US
$ 3.05
-3.79 %
$ 183 M
Market Cap
-3.14
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one ALDX stock under the worst case scenario is HIDDEN Compared to the current market price of 3.05 USD, Aldeyra Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one ALDX stock under the base case scenario is HIDDEN Compared to the current market price of 3.05 USD, Aldeyra Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one ALDX stock under the best case scenario is HIDDEN Compared to the current market price of 3.05 USD, Aldeyra Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ALDX

image
$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.0$3.0$3.0$2.0$2.0$1.0$1.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
0 REVENUE
0.00%
-60.1 M OPERATING INCOME
-40.48%
-55.9 M NET INCOME
-48.77%
-43.2 M OPERATING CASH FLOW
-42.48%
-44.9 M INVESTING CASH FLOW
-149.72%
-171 K FINANCING CASH FLOW
86.50%
0 REVENUE
0.00%
-10.4 M OPERATING INCOME
37.10%
-9.93 M NET INCOME
37.19%
-12.5 M OPERATING CASH FLOW
-3.60%
7.29 M INVESTING CASH FLOW
566.18%
1 M FINANCING CASH FLOW
12791.25%
Balance Sheet Aldeyra Therapeutics, Inc.
image
Current Assets 102 M
Cash & Short-Term Investments 101 M
Receivables 0
Other Current Assets 709 K
Non-Current Assets 2.75 M
Long-Term Investments 0
PP&E 267 K
Other Non-Current Assets 2.48 M
96.70 %Total Assets$104.6m
Current Liabilities 18.6 M
Accounts Payable 180 K
Short-Term Debt 303 K
Other Current Liabilities 18.1 M
Non-Current Liabilities 15 M
Long-Term Debt 15 M
Other Non-Current Liabilities 0
53.92 %44.64 %Total Liabilities$33.6m
EFFICIENCY
Earnings Waterfall Aldeyra Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 250 K
Gross Profit -250 K
Operating Expenses 60.1 M
Operating Income -60.1 M
Other Expenses -4.27 M
Net Income -55.9 M
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)0(250k)(250k)(60m)(60m)4m(56m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-78.66% ROE
-78.66%
-53.39% ROA
-53.39%
-69.65% ROIC
-69.65%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Aldeyra Therapeutics, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -55.9 M
Depreciation & Amortization 250 K
Capital Expenditures 0
Stock-Based Compensation 7.97 M
Change in Working Capital 5.91 M
Others 5.58 M
Free Cash Flow -43.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Aldeyra Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for ALDX of $11 , with forecasts ranging from a low of $10 to a high of $12 .
ALDX Lowest Price Target Wall Street Target
10 USD 227.87%
ALDX Average Price Target Wall Street Target
11 USD 260.66%
ALDX Highest Price Target Wall Street Target
12 USD 293.44%
Price
Max Price Target
Min Price Target
Average Price Target
121210108866442200Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 20
6. Ownership
Insider Ownership Aldeyra Therapeutics, Inc.
image
Sold
0-3 MONTHS
4.83 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
127 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. Per FDA agreement, the only. businesswire.com - 1 week ago
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in New York, New York. Dr. Brady's conversation with Clara Dong is scheduled to begin at 4:20 p. businesswire.com - 4 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK CITY, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Pending Securities Investigation; Contact BFA Law NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. accessnewswire.com - 1 month ago
ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX) NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. globenewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens Berman SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter (“CRL”) from the FDA for the resubmission of the New Drug Application (“NDA”) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. globenewswire.com - 1 month ago
8. Profile Summary

Aldeyra Therapeutics, Inc. ALDX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 183 M
Dividend Yield 0.00%
Description Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Contact 131 Hartwell Avenue, Lexington, MA, 02421 https://www.aldeyra.com
IPO Date May 2, 2014
Employees 9
Officers Laura Nichols Operations Manager Dr. Todd C. Brady M.D., Ph.D. Chief Executive Officer, President & Director Dr. Stephen G. Machatha Ph.D. Chief Development Officer Mr. Michael Alfieri Head of Finance and Principal Financial & Accounting Officer David Burke Head of Investor Relations